Hong Kong Healthtech Stock News

China Overseas Grand Oceans Group (SEHK:81) has put fresh numbers on the table for FY 2025, with first half revenue at C¥14.5b and basic EPS of C¥0.08. The trailing 12 month view shows revenue of C¥36.9b and EPS of C¥0.09 as the broader backdrop. Over the past three reported halves, revenue has moved from C¥21.9b in 1H 2024 to C¥24.0b in 2H 2024 and then to C¥14.5b in 1H 2025, with basic EPS shifting from C¥0.25 to C¥0.02 and then C¥0.08. This sets up a mixed picture that investors will weigh...

Essex Bio-Technology (SEHK:1061) has opened FY 2025 with first half revenue of HK$876.5 million and basic EPS of HK$0.29, setting the tone for how investors will read the latest set of numbers. The company has seen revenue move from HK$828.5 million in 1H 2024 to HK$858.2 million in 2H 2024 and then HK$876.5 million in 1H 2025, while basic EPS shifted from HK$0.28 to HK$0.26 and then HK$0.29 over the same periods. This gives a clear view of how the top and bottom lines are tracking into the...

WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of C¥5.9b and EPS of C¥1.22. The company has seen revenue move from C¥2.4b in the second half of 2024 to C¥3.2b in the second half of 2025, with basic EPS over that period shifting from C¥0.48 to C¥0.60 as investors weigh a trailing net margin of 24.9% against a slightly lower level a year ago. See...

Wondering whether China Petroleum & Chemical at HK$4.53 still offers value, or if the easy gains are behind it? This article walks through what the current price really reflects. The stock has seen a 5.0% decline over the last 7 days and a 16.3% decline over the last 30 days, yet it shows returns of 15.5% over 1 year, 23.5% over 3 years and 67.3% over 5 years. Recent market conversations around China Petroleum & Chemical have focused on how its share price performance lines up with broader...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Wondering whether Sichuan Kelun-Biotech Biopharmaceutical is still priced attractively, or if the easy value has already been taken? This breakdown focuses squarely on what you are paying versus what you are getting. The share price recently closed at HK$397.60, after a 4.4% decline over the last week and a 4.6% decline over the past month, while the 1 year return sits at 52.6%. Recent news coverage has focused on Sichuan Kelun-Biotech Biopharmaceutical in the context of investor interest in...

Why China Everbright Environment Group’s latest earnings matter for investors China Everbright Environment Group (SEHK:257) has drawn fresh attention after reporting full year 2025 earnings, with net income of HK$3,925.16 million and basic EPS of HK$0.639, alongside lower sales of HK$27,520.51 million. See our latest analysis for China Everbright Environment Group. The earnings update and focus on project expansion come after a period of steady share price gains, with a 1 month share price...

Tencent Holdings Limited recently reported fourth-quarter 2025 revenue of CNY 194,371 million and net income of CNY 58,260 million, alongside a proposed annual dividend of HKD 5.30 per share payable on June 1, 2026. At the same time, Tencent’s expanded push into AI agents, including integrating ClawBot into WeChat, has highlighted both its product innovation and investor concerns about how these AI initiatives will translate into clear monetization. Now we’ll examine how Tencent’s...

China e-commerce launch puts Global Chinese Business Club in focus Global Chinese Business Club (SEHK:1757) has drawn fresh attention after announcing plans for a new China business: a comprehensive e-commerce platform linking suppliers and consumers with O2O services and integrated B2B and B2C functions. See our latest analysis for Global Chinese Business Club. The recent China e-commerce announcement comes after a strong run in the shares, with a 30 day share price return of 51.19% and very...

Why United Laboratories’ latest guidance and insulin approval matter for investors United Laboratories International Holdings (SEHK:3933) has issued 2025 earnings guidance pointing to lower group profit, alongside a fresh China approval for its Insulin Degludec Injection, a combination that could reshape how investors think about its earnings mix. See our latest analysis for United Laboratories International Holdings. The share price has eased to HK$10.48, with a 1-day share price return of...

Zhaojin Mining Industry (SEHK:1818) has put solid numbers on the table for FY 2025 so far, with third quarter revenue at C¥5.5b and basic EPS of C¥0.17, while trailing 12 month revenue sits at C¥15.9b and EPS at C¥0.65. The company has seen revenue move from C¥3.5b and EPS of C¥0.13 in Q3 2024 to C¥5.5b and EPS of C¥0.17 in Q3 2025, alongside trailing 12 month net income of C¥2.4b that has helped lift margins from 9.8% to 15.2%. For investors, that combination of higher throughput and fatter...

Wondering if Haidilao International Holding at HK$15.85 is a bargain or a value trap? This article breaks down what the current price might actually reflect. The stock has had a mixed run, with a 10% year-to-date gain alongside 1% and 6% declines over the past 7 days and 30 days, and a 2.6% decline over the last year plus a 64.6% decline over five years that many investors still have in mind. Recent coverage has focused on Haidilao International Holding as a Hong Kong listed consumer...

China Petroleum & Chemical (SEHK:386) has released its FY 2025 numbers, reporting third quarter revenue of CNY 704.4b and basic EPS of CNY 0.069, against trailing twelve month revenue of CNY 2.8t and EPS of CNY 0.295355. Over recent quarters the company has reported revenue between CNY 673.7b and CNY 735.4b, while quarterly EPS has ranged from CNY 0.031453 to CNY 0.151207. This gives investors a clearer view of how earnings and the top line have tracked through the cycle. With net profit...

Greentown Service Group (SEHK:2869) has put fresh numbers on the board for FY 2025, with first half revenue of about C¥9.3b and basic EPS of C¥0.19 setting the tone for its latest earnings update. The company has seen first half revenue move from C¥8.2b in 2023 to C¥8.8b in 2024 and then to C¥9.3b in 2025. Over the same periods, basic EPS shifted from C¥0.13 to C¥0.16 and then to C¥0.19, giving a clear view of how the top and bottom line have tracked together. For investors, the current...

Dekon Food and Agriculture Group (SEHK:2419) has put fresh numbers on the table for FY 2025, with first half revenue at about C¥11.7b and basic EPS of C¥3.32, while the trailing twelve months show revenue of roughly C¥23.2b and basic EPS of C¥3.69. Over recent periods, the company has seen revenue move from about C¥9.4b in 1H 2024 to C¥13.1b in 2H 2024 and then to C¥11.7b in 1H 2025. Over the same time, EPS shifted from C¥4.54 to C¥6.00 and most recently C¥3.32, setting up a results season...

China Qinfa Group (SEHK:866) has completed a follow on equity offering and raised HK$315.9 million through a subsequent direct listing of 90,000,000 new ordinary shares at HK$3.51 each, expanding its share capital base. See our latest analysis for China Qinfa Group. At a share price of HK$3.94, China Qinfa Group has seen a 10.67% one-month share price return and a roughly 18x one-year total shareholder return, with momentum building over the past quarter as investors react to the capital...

Wynn Macau (SEHK:1128) has released its FY 2025 first half results, reporting revenue of HK$13.6b and basic EPS of HK$0.044. This marks a notable change from the HK$14.7b revenue and HK$0.305 EPS reported in 1H 2024, as well as the HK$14.0b revenue and HK$0.308 EPS recorded in 2H 2024. Trailing 12 month figures show revenue of HK$29.0b with basic EPS of HK$0.31. These numbers frame a results season in which investors are likely to focus on how thinner net margins are affecting the quality of...

Shanghai Henlius Biotech (SEHK:2696) has reported its FY 2025 results with first half revenue of C¥2.8b and basic EPS of C¥0.72, set against trailing 12 month revenue of C¥6.7b and EPS of C¥1.52 that give investors a fuller picture of its recent performance. Over recent periods, revenue has moved from C¥2.75b in 1H 2024 to C¥2.98b in 2H 2024 and C¥2.82b in 1H 2025, while EPS has tracked from C¥0.71 to C¥0.80 and then C¥0.72, leaving the current update framed by solid net income in the...

Sunshine Insurance Group (SEHK:6963) just released its full year 2025 results alongside a proposed final cash dividend of RMB 0.19 per ordinary share, a pairing that gives investors fresh income and earnings context. See our latest analysis for Sunshine Insurance Group. The latest HK$3.71 share price comes after a 1-day share price return of 0.54%, with the dividend and earnings announcement likely shaping how investors view Sunshine Insurance Group's risk and income profile. Despite a 30-day...

China Boqi Environmental (Holding) (SEHK:2377) has posted its FY 2025 first half numbers with revenue of C¥1,058.5 million and basic EPS of C¥0.166, against trailing twelve month revenue of C¥2,260.0 million and EPS of C¥0.285 that sit alongside a 20.6% uplift in earnings and an 11.7% net margin over the last year. The company has seen revenue move from C¥949.4 million in 1H FY 2024 to C¥1,058.5 million in 1H FY 2025, while basic EPS moved from C¥0.114 to C¥0.166 over the same halves. This...

XXF Group Holdings (SEHK:2473) has opened FY 2025 with first half revenue of C¥613.1 million and basic EPS of C¥0.014536, while the trailing 12 month line shows revenue of about C¥1.3 billion and EPS of C¥0.027649. Over the last three reported half years, revenue has moved from C¥504.3 million in 1H FY 2024 to C¥661.3 million in 2H FY 2024 and then C¥613.1 million in 1H FY 2025, with EPS stepping from C¥0.012725 to C¥0.013113 and most recently C¥0.014536. This sets up an earnings story where...

Deepexi Technology (SEHK:1384) has reported fresh numbers for FY 2025, with first half revenue of C¥132.1 million and a basic EPS loss of C¥1.12, while the trailing twelve months show revenue of C¥314.5 million and a basic EPS loss of C¥3.92. The company’s revenue moved from C¥129.0 million in 2H 2023 to C¥242.9 million in 2H 2024 and then to C¥132.1 million in 1H 2025. Net income excluding extra items shifted from a loss of C¥502.9 million in 2H 2023 to a loss of C¥1.25 billion in 2H 2024...

Sunac China Holdings (SEHK:1918) has issued unaudited earnings guidance for 2025, indicating an expected loss of RMB 12.0 billion to RMB 13.0 billion, compared with a loss of about RMB 25.70 billion in 2024. See our latest analysis for Sunac China Holdings. The updated 2025 guidance comes after a difficult stretch for shareholders, with a 1-year total shareholder return decline of 29.09% and a 5-year total shareholder return decline of 96.08%. The latest HK$1.17 share price reflects weaker...

Dingdang Health Technology Group (SEHK:9886) has posted its FY 2025 first half results with revenue of C¥2.3b, a basic EPS loss of C¥0.04 per share and net income loss of C¥51.7m, keeping the focus firmly on the path toward breakeven. Over the recent reporting periods, revenue has moved from C¥2.27b in 1H 2024 to C¥2.40b in 2H 2024 and C¥2.33b in 1H 2025, while basic EPS losses have shifted from C¥0.06 in 1H 2024 to C¥0.22 in 2H 2024 and C¥0.04 in 1H 2025. This sets up an earnings season...